Gossamer Bio (NASDAQ:GOSS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Gossamer Bio (NASDAQ:GOSS) to a hold rating in a report released on Saturday,Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research note on Tuesday, July 28th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Finally, Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Gossamer Bio has a consensus rating of “Hold” and a consensus target price of $256.00.

Gossamer Bio Trading Down 5.8%

NASDAQ:GOSS opened at $10.73 on Friday. Gossamer Bio has a 1-year low of $9.10 and a 1-year high of $309.60. The firm has a market capitalization of $31.44 million, a price-to-earnings ratio of -0.19 and a beta of 2.00. The business’s 50-day moving average price is $13.44 and its two-hundred day moving average price is $21.24.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new stake in Gossamer Bio during the 2nd quarter worth approximately $2,467,000. Kalehua Capital Management LLC acquired a new stake in Gossamer Bio during the 1st quarter worth approximately $3,363,000. ARCH Venture Management LLC bought a new position in Gossamer Bio in the second quarter valued at approximately $1,326,004. BlackRock Inc. bought a new position in Gossamer Bio in the second quarter valued at approximately $1,262,000. Finally, Corient Private Wealth LP bought a new position in Gossamer Bio in the second quarter valued at approximately $926,000. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.